If you have been reading about GHRH receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
=== Renewed hostilities (September–present) === In early September 2026, the US and Iran resumed trading attacks. Iran continued to use land-based batteries to intercept and obstruct commercial shipping lanes despite a US sanctions campaign, which led to the lowest transit rates through the Strait of Hormuz since the start of the war. After the Yemeni civil war escalated significantly, the conflict spread to a second maritime front. The Strait of Bab al-Mandab crisis began when Iran-backed Houthi forces launched an offensive against the internationally recognized Saudi-backed government along Yemen's western coast. Houthi fighters took control of the Hanish Islands, Perim Island, the coastal town of Dhubab, and the strategically important port city of Mokha during the offensive. The group gained control of the Strait of Bab al-Mandab, a vital global chokepoint, as a result of this advance. On 22 September, indirect "shuttle talks" between Iranian Foreign Minister Abbas Araghchi and US envoys Jared Kushner and Steve Witkoff through international mediators briefly resumed on the sidelines of the United Nations General Assembly in New York City. Iran reiterated its demands for permanent peace through communications sent through a Qatari mediator, including the complete lifting of the naval blockade, the immediate release of frozen Iranian financial assets, the end of the war on all fronts, and the halt to US military actions.
A study on Neanderthal teeth from the Chagyrskaya Cave in the Altai Mountains (Russia), indicating that the studied sample overall falls within the known Neanderthal phenotypic variability but also preserves specific morphological traits, is published by Gicqueau et al. (2026). Massilani et al. (2026) present a high-quality genome of an approximately 110,000-years-old Neanderthal individual from the Denisova Cave (Russia), providing evidence of a closer relationship of the studied individual to a 120,000-years-old Neanderthal from the same cave than to a 80,000-years-old individual from the Chagyrskaya Cave or to European Neanderthals, evidence of gene flow from Denisovans in both Neanderthals from the Denisova Cave, and evidence of differentiation between Altai and European Neanderthals comparable to that of the most differentiated populations of modern humans. Zubova et al. (2026) report evidence of deliberate invasive dental caries intervention in a 59,000-years-old Neanderthal molar from the Chagyrskaya Cave. Evidence from the study of rhinocerotid remains from Middle Paleolithic sites in France and Spain, interpreted as consistent with use of rhinoceros teeth as tools (including soft hammers and anvils) by Neanderthals, is presented by Sanz-Royo et al. (2026). Picin et al.
Global Fossil Infrastructure Tracker API – the trade association of the US oil industry. (American Petroleum Institute) U.S. Energy Information Administration U.S. Department of Energy EIA – World supply and consumption Joint Organisations Data Initiative | Oil and Gas Data Transparency U.S. National Library of Medicine: Hazardous Substances Databank – Crude Oil "Petroleum" . The American Cyclopædia. 1879. "A Short History of Petroleum", Scientific American, August 10, 1878, p. 85
Sources: en.wikipedia.org
Iron-sulfur protein NUBPL (IND1) also known as nucleotide-binding protein-like (NUBPL), IND1 homolog, Nucleotide-binding protein-like or huInd1 is an iron-sulfur (Fe/S) protein that, in humans, is encoded by the NUBPL gene, located on chromosome 14q12. It has an early role in the assembly of the mitochondrial complex I assembly pathway. NUBPL is located on the q arm of chromosome 14 in position 12 and has 18 exons. The NUBPL gene produces a 5.9 kDa protein composed of 54 amino acids. The structure of the protein includes a presumed iron-sulfur binding (CxxC) signature, a nucleotide-binding domain which has been highly conserved, and a mitochondrial targeting sequence in the N-terminal. NUBPL is required for the assembly of complex I, which is composed of 45 evolutionally conserved core subunits, including both mitochondrial DNA and nuclear encoded subunits. One of its arms is embedded in the inner membrane of the mitochondria, and the other is embedded in the organelle. The two arms are arranged in an L-shaped configuration. The total molecular weight of the complex is 1MDa.
== Radioactivity over time == Fission products have half-lives of 90 years (samarium-151) or less, except for seven long-lived fission products that have half-lives of 211,100 years (technetium-99) or more. Therefore, the total radioactivity of a mixture of pure fission products decreases rapidly for the first several hundred years (controlled by the short-lived products) before stabilizing at a low level that changes little for hundreds of thousands of years (controlled by the seven long-lived products). This behavior of pure fission products with actinides removed, contrasts with the decay of fuel that still contains actinides. This fuel is produced in the so-called "open" (i.e., no nuclear reprocessing) nuclear fuel cycle. A number of these actinides have half-lives in the missing range of about 100 to 200,000 years, causing some difficulty with storage plans in this time-range for open-cycle non-reprocessed fuels. Proponents of nuclear fuel cycles which aim to consume all their actinides by fission, such as the Integral Fast Reactor and molten salt reactor, use this fact to claim that within 200 years, their fuel wastes are no more radioactive than the original uranium ore. Fission products primarily emit beta radiation, while actinides primarily emit alpha radiation. Many of each also emit gamma radiation.
=== Pharmacokinetics === After oral intake, ertugliflozin is practically completely absorbed from the gut and undergoes no relevant first-pass effect. Highest blood plasma concentrations are reached after one hour. When in circulation, 93.6% of the substance are bound to plasma proteins. Ertugliflocin is metabolised mainly to glucuronides by the enzymes UGT1A9 and UGT2B7. Cytochrome P450 enzymes play only a minor role in its metabolism. The elimination half-life is estimated to be 17 hours. 40.9% are eliminated via the feces (33.8% in unchanged form and 7.1% as metabolites) and 50.2% via the urine (1.5% unchanged and 48.7% as metabolites). The high proportion of unchanged substance in the feces is probably due to hydrolysis of the metabolites back to the parent substance.
[...] The staffs concerned must have planned this for months – they had to formulate an overall operations plan, to move in the stocks necessary for the battle, to plan and to allocate the aviation resources for the deployment of troops to Georgia and other logistic capabilities, to produce a target list for the air force, and so on. [...] the scope and intensity of their attack exceeded the forecasts made by the Georgian leadership and the Western countries. The Russians achieved a strategic advantage by way of using the element of surprise." He pointed out that most of the Russian military units that fought in Georgia belonged to the North Caucasus Military District, whose capabilities surpass every other Russian districts. In June 2009, Svante Cornell wrote, "Many scholars have now shown Russia's invasion of Georgia had been long in the planning, premeditated and intended to deal a mortal blow to what Moscow saw as western encroachment in its backyard. Whatever mistakes the Georgian government may have made in being lured into war, there is little doubt Moscow provoked the conflict to bully its neighbors into submission." According to Cornell, the Kremlin spent millions in an international information campaign to blame Georgia for the war; however, there is evidence, including some in Russian media, that Russia actually started the war.
Sources: en.wikipedia.org
A peptide microarray (also commonly known as peptide chip or peptide epitope microarray) is a collection of peptides displayed on a solid surface, usually a glass or plastic chip. Peptide chips are used by scientists in biology, medicine and pharmacology to study binding properties and functionality and kinetics of protein-protein interactions in general. In basic research, peptide microarrays are often used to profile an enzyme (like kinase, phosphatase, protease, acetyltransferase, histone deacetylase etc.), to map an antibody epitope or to find key residues for protein binding. Practical applications are seromarker discovery, profiling of changing humoral immune responses of individual patients during disease progression, monitoring of therapeutic interventions, patient stratification and development of diagnostic tools and vaccines.
===== Lawsuits ===== In October 2017, The New Yorker published a story on Mortimer Sackler and Purdue Pharma regarding their ties to the production and manipulation of the oxycodone markets. The article links Raymond and Arthur Sackler's business practices with the rise of direct pharmaceutical marketing and eventually to the rise of addiction to oxycodone in the United States. The article implies that the Sackler family bears some responsibility for the opioid epidemic in the United States. In 2019, The New York Times ran a piece confirming that Richard Sackler, the son of Raymond Sackler, told company officials in 2008 to "measure our performance by Rx's by strength, giving higher measures to higher strengths". This was verified with documents tied to a lawsuit – which was filed by the Massachusetts attorney general, Maura Healey – claiming that Purdue Pharma and members of the Sackler family knew that high doses of OxyContin over long periods would increase the risk of serious side effects, including addiction. Despite Purdue Pharma's proposal for a US$12 billion settlement of the lawsuit, the attorneys general of 23 states, including Massachusetts, rejected the settlement offer in September 2019.
Daptomycin is a cyclic lipopeptide antibiotic produced by Streptomyces filamentosus. Daptomycin consists of 13 amino acids, 10 of which are arranged in a cyclic fashion, and three on an exocyclic tail. Two nonproteinogenic amino acids exist in the drug, the unusual amino acid L-kynurenine (Kyn), only known to daptomycin, and L-3-methylglutamic acid (mGlu). The N-terminus of the exocyclic tryptophan residue is coupled to decanoic acid, a medium-chain (C10) fatty acid. Biosynthesis is initiated by the coupling of decanoic acid to the N-terminal tryptophan, followed by the coupling of the remaining amino acids by nonribosomal peptide synthetase (NRPS) mechanisms. Finally, a cyclization event occurs, which is catalyzed by a thioesterase enzyme, and subsequent release of the lipopeptide is granted. The NRPS responsible for the synthesis of daptomycin is encoded by three overlapping genes, dptA, dptBC and dptD. The dptE and dptF genes, immediately upstream of dptA, are likely to be involved in the initiation of daptomycin biosynthesis by coupling decanoic acid to the N-terminal Trp. These novel genes (dptE, dptF) correspond to products that most likely work in conjunction with a unique condensation domain to acylate the first amino acid (tryptophan). These and other novel genes (dptI, dptJ) are believed to be involved in supplying the nonproteinogenic amino acids L-3-methylglutamic acid and Kyn; they are located next to the NRPS genes. The decanoic acid portion of daptomycin is synthesized by fatty acid synthase machinery (Figure 2).
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.